Quarterly Activities/Appendix 4C Cash Flow Report
Released
Released
Announcement PDF
ASX Announcement
Enlitic, Inc.
ARBN 672 254 027
1
31 July 2026
Quarterly Activity Report & Appendix 4C
Q2 FY26
Highlights
Cash flow: Net operating cash outflow of US$0.7m, down 76% from the prior
quarter (Q1 FY26: US$2.9m).
Cash receipts: US$2.3m for the quarter (Q1 FY26: US$0.4m), reflecting collection
of receivables on contracts signed in prior periods.
Cost discipline: Cost discipline remains in place with total operating expenditure
reducing to US$3.0m (Q1 FY26: US$3.3m). The Company will continue to manage
its monthly burn.
Contract execution and pipeline: 17 new client agreements signed (Q1 FY26: 17),
weighted to lower-value migration contracts this quarter (total contract value
~US$1.0m / ~A$1.4m1
).
RHCNZ Go-Live: Ensight went live at RHCNZ Medical Imaging Group, New
Zealand's largest private radiology provider, validating Enlitic's Intelerad
integration in a live production environment.
Lumus Imaging: Signed Enlitic's first Australian Ensight subscription, a three-
year agreement with Lumus Imaging deploying the full platform across three use
cases.
Ensight momentum: Continued Ensight adoption through the Intelerad channel,
including additional go-lives and new Ensight client signings, building the
recurring subscription base.
Placement: Post quarter-end, binding commitments received for a ~A$15m
conditional placement subject to: (i) obtaining shareholder approval (obtained
on 29 July 2026); and (ii) conversion of convertible notes. Subject to completion,
Enlitic is expected to have a pro forma cash balance of ~A$18m2
and, per the
Company's current expectations, funds raised from the conditional placement
should be sufficient to fund operations through to cashflow break-even.
1
US$1.0m converted based on a USD:AUD exchange rate of 0.7098, being the average exchange rate for Q2
FY26. The average USD:AUD exchange rate for Q1 FY26 was 0.6942.
2
US$2.1m converted based on a USD:AUD exchange rate of 0.6915, being the exchange rate at 30 June 2026.
Enlitic, Inc.
ARBN 672 254 027
2
Convertible note conversion: Post quarter-end, noteholders agreed to convert
existing convertible notes into CDIs (on amended terms) subject to certain
conditions (including obtaining shareholder approval, obtained on 29 July 2026)
to simplify the capital structure and move to a debt-free balance sheet.
SPP: Post quarter-end, the Company announced that, subject to obtaining any
necessary ASX waivers (subsequently obtained as announced on 14 July 2026)
and shareholder approval (obtained on 29 July 2026), the Company will offer
eligible CDI holders the opportunity to participate in a security purchase plan
(“SPP”) which targets to raise up to ~A$1 million.
Medical technology software company leveraging artificial intelligence to improve the
management and utility of medical imaging data, Enlitic, Inc. (ASX: ENL) (“Enlitic” or “the
Company”), is pleased to provide this Quarterly Activity Report and Appendix 4C for the
quarter ended 30 June 2026 (“Q2 FY26”).
Michael Sistenich, CEO of Enlitic, said:
“Post quarter-end, our most significant development was securing the capital required to
execute our strategy. The ~A$15 million conditional placement, together with the
conversion of our convertible notes, is expected to leave Enlitic debt-free with pro forma
cash of ~A$18 million2
and, on completion, sufficient cash to fund operations through to
expected cashflow break-even. With shareholder approval now having been obtained and
the remaining implementation steps progressing as planned, the Company expects these
funding transactions to complete which will position the Company to advance its strategy
with a strengthened capital base.
We also cut our net operating cash outflow for Q2 FY26 by 76% on the prior quarter,
holding our cost base down while continuing to collect on prior contracts. The discipline
we put in place over the past year is now reflected in the numbers.
Commercially, we are executing on the land-and-expand model that sits at the core of
our strategy. The go-live at RHCNZ and our first Australian Ensight subscription with
Lumus show the platform performing in live enterprise environments, and our OEM
channel continues to convert the installed migration base into recurring, high-margin
subscription revenue.
With the funding transactions expected to complete shortly, we now move into the
remainder of the year with a clear focus on execution. Our priorities are to deliver
customer go-lives, progress the deployment of Ensight across new and existing
customers, and continue building recurring subscription revenue through our OEM and
partner channels.”
Enlitic, Inc.
ARBN 672 254 027
3
Capital structure & funding
Subsequent to quarter end, the Company announced binding commitments to raise
~A$15m (before costs) through a conditional placement of new CDIs at A$0.004 per new
CDI, together with a security purchase plan to raise up to a further ~A$1m. Alongside the
conditional placement, the Company also announced the proposed conversion of its
existing convertible notes and a proposed 10:1 share consolidation / reverse share split. At
the Extraordinary General (Special) Meeting held on 29 July 2026, shareholders approved
all resolutions relating to the conditional placement, the convertible note conversion, the
SPP and the share consolidation. Completion of the conditional placement, and conversion
of the convertible notes, remains subject to the satisfaction of the remaining conditions.
Further details, including the indicative timetable and key risks, are set out in the
Company’s ASX announcements dated 3 July 2026, 14 July 2026 and 16 July 2026and the
Company’s investor presentation released to ASX on 3 July 2026.
Subject to completion, the conditional placement and conversion of convertible notes are
expected to leave Enlitic debt-free with pro forma cash of ~A$18m2
and a targeted runway
of more than 12 months. Based on the Company’s current budgets and expectations, the
available funds are expected to be sufficient to fund ongoing operations through to
expected operational cash flow break-even, although this is not guaranteed. The proceeds
are intended to fund continued commercialisation, sales and marketing scale-up, working
capital and balance sheet support. Settlement of the conditional placement is expected
on or around 5 August 2026.
Operational highlights
Sustained customer growth
Total contract value signed during the quarter was ~US$1.0m (~A$1.4m1
), compared with
~US$3.52m (A$5.1m1
) in Q1 FY26. The lower quarterly value reflected a greater weighting
toward smaller engagements and the timing of larger enterprise opportunities. On a
moving 12-month basis, signed contract value remained strong at ~US$9.39m, a decrease
of 4.7% (Q1 FY26: ~US$9.86) and a ~31% increase above the ~US$7.19m reported at Q4
FY25.
Enlitic signed 17 new client agreements in Q2 FY26 (Q1 FY26: 17), of lower average value,
spanning migration technology contracts and Ensight software licence agreements.
Commercial momentum through the Intelerad channel continued during the quarter, with
further Ensight go-lives and new Ensight client signings that expand the Company's
recurring subscription base.
Notable contracts executed included:
Enlitic, Inc.
ARBN 672 254 027
4
Lumus; three-year Ensight subscription with total contract value of US$248k
across Hanging Protocols, de-identification and AI validation (ASX:1 July 2026);
Radiology Consultants of Iowa (3 year subscription – total contract value US$143k);
and
OEM migration contracts totalling US$480k.
This commercial momentum is supported by an expanding customer and OEM base. As
set out in the investor presentation released to ASX on 3 July 2026, Enlitic has 8 signed
OEM agreements, 6 live OEM integrations in market and 983 total sites onboarded (727
live, with a further 256 expected to go live in 2H 2026), with 7 customers expected to go
live over the half. Through OEM integrations, Enlitic expects to compress its enterprise
sales cycle from the historical 18 to 24 months toward ~6 months, supporting faster
conversion of pipeline to revenue.
Note: TCV refers to total contract value. US dollar amounts are presented in US$000.
Corporate summary
Financial Performance & Cash Flow Summary
Unaudited revenue totalled US$0.9m, an increase of 14.2% from the prior quarter (Q1 FY26:
US$0.8m). Revenue recognition remains influenced by the delivery schedule of a major
global healthcare customer program, whose scope and overall contract value increased.
More substantive components of the program are expected to be delivered across H2
FY26, subject to delivery milestones and customer program schedules.
849
1,146
1,450
1,798
2,465 2,348
7,190
9,858 9,392
0
2000
4000
6000
8000
10000
12000
-
500
1,000
1,500
2,000
2,500
3,000
Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
Annual
TCV
$'000
Quarterly
TCV
US$'000
Customer Contracts: Moving Quarterly & Annual TCV
Qtrly Moving Average Annual Moving Average
Enlitic, Inc.
ARBN 672 254 027
5
Continued cost discipline and efficiency
The cost reduction measures implemented in January 2026 are now substantially
reflected in the quarterly cost base. Total operating expenditure fell to US$3.0m from
US$3.3m in Q1 FY26, with reductions across staff, research and development and
operating costs partly offset by higher corporate costs as the Company scaled ahead of
the capital raising. The cost base is expected to remain disciplined as the Company scales
its Ensight subscription revenue.
Cash receipts for the quarter were US$2.3m, compared to US$0.4m in the previous
quarter, reflecting the collection of receivables from contracts commenced in prior
periods. Together with continued cost discipline, this drove a net operating cash outflow
of US$0.7m for the period, down 76% from US$2.9m in the previous quarter.
Enlitic’s
cash balance at 30 June 2026 was US$2.05m, compared to US$2.97m at the prior quarter
end. This balance predates the ~A$15m conditional placement announced on 3 July 2026
(refer Capital Structure & Funding above), which on completion is expected to deliver pro
forma cash of ~A$18m2
.
4,678
4,007
3,559
3,798
3,286
3,042
0
1,000
2,000
3,000
4,000
5,000
Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
US
$'000
AXIS TITLE
Expenditure by Qtr - 25/26
(3,938)
(3,290)
(836)
(3,324)
(2,881)
(698)
(6,000)
(4,000)
(2,000)
0
Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
AUS
$'000
AXIS TITLE
Operating Cash Flow by Qtr - 25/26
Enlitic, Inc.
ARBN 672 254 027
6
In accordance with ASX Listing Rule 4.7C.3, payments to related parties and their
associates during Q2 FY26 amounted to US$139k in aggregate, comprising cash paid to
Directors and Non-Executive Directors for salaries, travel and reimbursement of
applicable costs.
Financial Outlook
Enlitic continues to move through H2 FY26 focused on converting its commercial pipeline,
delivering the seven scheduled customer go-lives and progressing the 256 sites expected
to enter production, including the Lumus deployment. The Company will also continue
expanding Ensight adoption through its OEM integrations and partner channels.
Continued delivery across major enterprise programs, disciplined expenditure and,
subject to completion, the strengthened balance sheet from the capital raising and
associated transactions are expected to support revenue growth and progress toward
operational cash flow break-even. The timing of contract conversion, deployment and
revenue recognition remains subject to customer procurement, implementation and
program schedules.
The Company continued to demonstrate strong cost discipline and operational efficiency
while supporting increased commercial activity.
This announcement was authorised for release by the Board of Enlitic, Inc.
– ENDS –
Enquiries
Enlitic Investor Relations
Australia:
invest_au@enlitic.com
Henry Jordan
Six Degrees Investor Relations
_+61 (0) 431 271 538
About Enlitic
Enlitic is a software company that uses artificial intelligence to develop software products
that manage medical imaging data in radiology (such as MRI, CT scans, X-ray and
ultrasound images) and licences such products to healthcare providers. Enlitic’s products
(including its current product offering and product suite under development) seek to
standardise, protect, integrate, and analyse data to create the foundation of a real-world
evidence platform that can improve clinical workflows, increase efficiencies, and expand
capacity. Read more at enlitic.com.
Enlitic, Inc.
ARBN 672 254 027
7
Enlitic’s CDIs are traded on ASX in reliance on the safe harbour provisions of Regulation S
under the US Securities Act of 1933 as amended, and in accordance with the procedures
established pursuant to the provisions of a no action letter dated 7 January 2000 given
to ASX by the staff at the US Securities and Exchange Commission. The relief was given
subject to certain procedures and conditions described in the no action letter. One of the
conditions is that the issuer provides notification of the Regulation S status of its securities
in communications such as this announcement.
Forward-looking statements
Certain statements made during or in connection with this announcement contain or
comprise certain forward-looking statements regarding the Company, its projected cash
flow, financial performance, its customer contracts and customer pipeline and product
development. Although the Company believes that the expectations reflected in such
forward-looking statements are reasonable, such expectations are only predictions and
are subject to inherent risks and uncertainties which could cause actual values, results,
performance or achievements to differ materially from those expressed, implied or
projected in any forward looking statements and no assurance can be given that such
expectations will prove to have been correct.
Accordingly, results could differ materially from those set out in the forward-looking
statements as a result of, among other factors, changes in economic and market
conditions, delays or changes in product development and realisation of customer
pipeline, changes in demand, success of business and operating initiatives, changes in the
regulatory environment and other government actions, fluctuations in exchange rates and
business and operational risk management.
To the maximum extent permitted by law, each of the Company, its officers, employees
and advisers expressly disclaim any responsibility for the accuracy or completeness of
the material contained in these forward-looking statements and excludes all liability
whatsoever (including in negligence) for any loss or damage which may be suffered by any
person as a consequence of any information in forward-looking statements or any error
or omission. The Company undertakes no obligation to update publicly or release any
revisions to these forward-looking statements to reflect events or circumstances after
today's date or to reflect the occurrence of unanticipated events other than required by
the applicable laws, including the ASX Listing Rules. Accordingly, you should not place
undue reliance on any forward-looking statement.
Rule 4.7B
ASX Listing Rules Appendix 4C (17/07/20) Page 1
+ See chapter 19 of the ASX Listing Rules for defined terms.
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
ENLITIC, INC.
ABN Quarter ended (“current quarter”)
ARBN 672 254 027 June 30 2026
Consolidated statement of cash flows Current quarter
$US’000
Year to date (6
months)
$US’000
1. Cash flows from operating activities
2,334 2,737
1.1 Receipts from customers
1.2 Payments for
(788) (1,784)
(a) research and development
(b) product manufacturing and operating
costs
(150) (403)
(c) advertising and marketing (94) (180)
(d) leased assets - -
(e) staff costs (1,473) (2,982)
(f) administration and corporate costs (537) (979)
1.3 Dividends received (see note 3)
1.4 Interest received 10 12
1.5 Interest and other costs of finance paid - -
1.6 Income taxes paid
1.7 Government grants and tax incentives
1.8 Other (provide details if material)
1.9 Net cash from / (used in) operating
activities
(698) (3,579)
2. Cash flows from investing activities
2.1 Payments to acquire or for:
(a) entities
(b) businesses
(c) property, plant and equipment (4) (4)
(d) investments
(e) intellectual property
(f) other non-current assets
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
ASX Listing Rules Appendix 4C (17/07/20) Page 2
+ See chapter 19 of the ASX Listing Rules for defined terms.
Consolidated statement of cash flows Current quarter
$US’000
Year to date (6
months)
$US’000
2.2 Proceeds from disposal of:
(a) entities
(b) businesses
(c) property, plant and equipment
(d) investments
(e) intellectual property
(f) other non-current assets
2.3 Cash flows from loans to other entities
2.4 Dividends received (see note 3)
2.5 Other (provide details if material)
2.6 Net cash from / (used in) investing
activities
(4) (4)
3. Cash flows from financing activities
- -
3.1 Proceeds from issues of equity securities
(excluding convertible debt securities)
3.2 Proceeds from issue of convertible debt
securities
- 3,707
3.3 Proceeds from exercise of options - -
3.4 Transaction costs related to issues of
equity securities or convertible debt
securities
(223) (726)
3.5 Proceeds from borrowings
3.6 Repayment of borrowings
3.7 Transaction costs related to loans and
borrowings
3.8 Dividends paid
3.9 Other (provide details if material)
3.10 Net cash from / (used in) financing
activities
(223) 2,981
4. Net increase / (decrease) in cash and
cash equivalents for the period
2,966 2,569
4.1 Cash and cash equivalents at beginning of
period
4.2 Net cash from / (used in) operating
activities (item 1.9 above)
(698) (3,579)
4.3 Net cash from / (used in) investing activities
(item 2.6 above)
(4) (4)
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
ASX Listing Rules Appendix 4C (17/07/20) Page 3
+ See chapter 19 of the ASX Listing Rules for defined terms.
Consolidated statement of cash flows Current quarter
$US’000
Year to date (6
months)
$US’000
4.4 Net cash from / (used in) financing activities
(item 3.10 above)
(223) 2,981
4.5 Effect of movement in exchange rates on
cash held
11 85
4.6 Cash and cash equivalents at end of
period
2,052 2,052
5. Reconciliation of cash and cash
equivalents
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the accounts
Current quarter
$US’000
Previous quarter
$US’000
5.1 Bank balances 2,052 2,966
5.2 Call deposits
5.3 Bank overdrafts
5.4 Other (provide details)
5.5 Cash and cash equivalents at end of
quarter (should equal item 4.6 above)
2,052 2,966
6. Payments to related parties of the entity and their
associates
Current quarter
$US'000
6.1 Aggregate amount of payments to related parties and their
associates included in item 1
-
6.2 Aggregate amount of payments to related parties and their
associates included in item 2
139
Cash Paid for Directors and Non-Executive Directors in quarter 2 amounted to US$139k which includes salaries, travel and
reimbursement of any costs.
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
ASX Listing Rules Appendix 4C (17/07/20) Page 4
+ See chapter 19 of the ASX Listing Rules for defined terms.
7. Financing facilities
Note: the term “facility’ includes all forms of financing
arrangements available to the entity.
Add notes as necessary for an understanding of the
sources of finance available to the entity.
Total facility
amount at quarter
end
$US’000
Amount drawn at
quarter end
$US’000
7.1 Loan facilities - -
7.2 Credit standby arrangements - -
7.3 Other (please specify) - -
7.4 Total financing facilities - -
7.5 Unused financing facilities available at quarter end -
7.6 Include in the box below a description of each facility above, including the lender, interest
rate, maturity date and whether it is secured or unsecured. If any additional financing
facilities have been entered into or are proposed to be entered into after quarter end,
include a note providing details of those facilities as well.
8. Estimated cash available for future operating activities $US’000
8.1 Net cash from / (used in) operating activities (item 1.9) (698)
8.2 Cash and cash equivalents at quarter end (item 4.6) 2,052
8.3 Unused finance facilities available at quarter end (item 7.5) -
8.4 Total available funding (item 8.2 + item 8.3) 2,052
8.5 Estimated quarters of funding available (item 8.4 divided by
item 8.1)
2.94
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a
figure for the estimated quarters of funding available must be included in item 8.5.
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1 Does the entity expect that it will continue to have the current level of net operating
cash flows for the time being and, if not, why not?
Answer:
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further
cash to fund its operations and, if so, what are those steps and how likely does it
believe that they will be successful?
Answer:
8.6.3 Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?
Answer:
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
ASX Listing Rules Appendix 4C (17/07/20) Page 5
+ See chapter 19 of the ASX Listing Rules for defined terms.
Compliance statement
1 This statement has been prepared in accordance with accounting standards and policies
which comply with Listing Rule 19.11A.
2 This statement gives a true and fair view of the matters disclosed.
Date: ...................................................................................
Authorised by: The Board
(Name of body or officer authorising release – see note 4)
Notes
1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the
entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An
entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is
encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions
in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been
prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities,
depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”.
If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the
[name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a
disclosure committee, you can insert here: “By the Disclosure Committee”.
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as
complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and
Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial
records of the entity have been properly maintained, that this report complies with the appropriate accounting standards
and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a
sound system of risk management and internal control which is operating effectively.
31 July 2026
Share your feedback
Discover